Gantenerumab: a novel human anti-Aβ antibody demonstrates sustained cerebral amyloid-β binding and elicits cell-mediated removal of human amyloid-β - Test2 - elhamkhani - TriplyDB

Gantenerumab: a novel human anti-Aβ antibody demonstrates sustained cerebral amyloid-β binding and elicits cell-mediated removal of human amyloid-β

Gantenerumab: a novel human anti-Aβ antibody demonstrates sustained cerebral amyloid-β binding and elicits cell-mediated removal of human amyloid-β

http://www.wikidata.org/entity/Q27674567

about

Current Research Therapeutic Strategies for Alzheimer's Disease Treatment Targeting the proper amyloid-beta neuronal toxins: a path forward for Alzheimer's disease immunotherapeutics Immunotherapy for Alzheimer's disease: hoops and hurdles Advances in Alzheimer's disease drug development Profile of gantenerumab and its potential in the treatment of Alzheimer's disease Bapineuzumab captures the N-terminus of the Alzheimer's disease amyloid-beta peptide in a helical conformation Crystal structure reveals conservation of amyloid-β conformation recognized by 3D6 following humanization to bapineuzumab Immunotherapeutic approaches for Alzheimer's disease An anti-pyroglutamate-3 Aβ vaccine reduces plaques and improves cognition in APPswe/PS1ΔE9 mice Biomarkers in amyloid-β immunotherapy trials in Alzheimer's disease.Evaluation of a DNA Aβ42 vaccine in adult rhesus monkeys (Macaca mulatta): antibody kinetics and immune profile after intradermal immunization with full-length DNA Aβ42 trimer.Combined immunotherapy with "anti-insulin resistance" therapy as a novel therapeutic strategy against neurodegenerative diseases.A novel monoclonal antibody against the N-terminus of Aβ1-42 reduces plaques and improves cognition in a mouse model of Alzheimer's disease.Combined treatment with a BACE inhibitor and anti-Aβ antibody gantenerumab enhances amyloid reduction in APPLondon mice.Activity-modulating monoclonal antibodies to the human serine protease HtrA3 provide novel insights into regulating HtrA proteolytic activities.Amyloid-beta: a crucial factor in Alzheimer's disease.Molecular basis for mid-region amyloid-β capture by leading Alzheimer's disease immunotherapies.Amyloid-ß-directed immunotherapy for Alzheimer's disease.Novel immunological approaches for the treatment of Alzheimer's disease.Tau aggregation and its interplay with amyloid-β.Encapsulated cellular implants for recombinant protein delivery and therapeutic modulation of the immune system.Advances in recent patent and clinical trial drug development for Alzheimer's disease.Electroacupuncture Reduces Aβ Production and BACE1 Expression in SAMP8 Mice.TREM2 deficiency reduces the efficacy of immunotherapeutic amyloid clearance Comparing the efficacy and neuroinflammatory potential of three anti-abeta antibodies Anti-Aβ antibodies incapable of reducing cerebral Aβ oligomers fail to attenuate spatial reference memory deficits in J20 mice.Immunotherapeutic Approaches Targeting Amyloid-β, α-Synuclein, and Tau for the Treatment of Neurodegenerative Disorders.Amyloid Hypothesis: Is There a Role for Antiamyloid Treatment in Late-Life Depression?A multifunctional therapeutic approach to disease modification in multiple familial mouse models and a novel sporadic model of Alzheimer's disease.Advances in the development of vaccines for Alzheimer's disease.Targeting receptor-mediated transport for delivery of biologics across the blood-brain barrier.Pre-amyloid oligomers budding:a metastatic mechanism of proteotoxicity.Immunotherapy with Aducanumab Restores Calcium Homeostasis in Tg2576 Mice.Structure of Crenezumab Complex with Aβ Shows Loss of β-Hairpin.Amyloid-beta immunotherapy: the hope for Alzheimer disease?Alzheimer's disease in people with Down's syndrome: the prospects for and the challenges of developing preventative treatments Immunotherapy for neurodegenerative diseases: focus on α-synucleinopathies.Treating Alzheimer's disease with monoclonal antibodies: current status and outlook for the future Open questions for Alzheimer's disease immunotherapy.Anti-amyloid beta to tau - based immunization: Developments in immunotherapy for Alzheimer disease.

P2860

Q26765530-C39022BA-1106-40CA-8B8F-710C9D166112 Q26822002-246CBE92-72C5-48D0-81E2-E59E2F9DC22B Q26823877-D4EFED58-8924-4BD0-9DB4-41BFE9A2DCAD Q26849352-92BE7E8A-D22B-4A89-8E69-60D3A92166F9 Q27027675-60EAAA0C-A729-418D-8974-7D38931F5C8F Q27676409-6E77AFEE-0E48-426F-84C4-FDD83DF53F76 Q27684692-92D0FA32-F2C1-4CE1-90A2-508C14294873 Q28081278-3EBC1E80-AC6C-4200-B7E7-EA55AD21AAC4 Q30316057-D0C8CBEA-94AA-4E29-9677-4A16127432C1 Q30651551-54C53C94-6182-4C78-BE4B-E7F99A23B938 Q33604583-8696A478-A780-482B-9B5E-649EFDA36E20 Q33731321-5B3DFB1F-A8E5-434C-A32E-2CABF6EC548F Q33853280-DE219137-E05D-4FEB-921C-1BEE850979D4 Q34091134-273A13D1-C675-4594-963F-C046C4C601F8 Q34232310-B8CC3380-562C-4BB9-A822-7920F93C7C70 Q34451907-96671403-01EA-4518-8E5C-1D7F4DCE7A58 Q34472054-6B02BB91-CF79-4B1C-AB2A-181662169770 Q34548700-DCEC7EDC-7EC2-4E11-BB1E-9E9C30D2B857 Q34562675-9B052419-736D-4AE6-9DF4-299DC3E15AA9 Q35008256-7C792D01-3B4B-460A-AFD5-F1CDDF6F4CC8 Q35723422-B38AB802-ABC0-4716-B030-CFEDADDDBAB1 Q35738142-7E7C28D6-88B3-4698-B708-F68DC8F28647 Q35898132-BC4DB61A-77E0-447D-966A-467DE4C5E4FB Q36073450-083C455A-85A0-45E3-A7FC-2D5EFBC766D4 Q36181289-13B1EF4F-9566-4E6E-9CA9-2F133A2A4490 Q36269285-6CDFCC80-4E68-4346-AD3B-EFDAE6C6EE11 Q36484413-CC716C3D-7C81-4ABC-AA4F-7B31DA15AFC2 Q36711795-A908AE69-7A9D-44AC-A347-5CC9F1AEC459 Q36850925-3B4BCAAF-8791-497E-840D-78CAF5103B97 Q36965988-8B241EF1-FDA7-455A-AF14-30569F86417A Q37312010-4F46E2C1-6258-4E8E-A8CD-A079F06CC550 Q37360313-1A3E8857-1D9B-4FCE-AC0A-8251B61A9EA7 Q37504954-BE33BB7E-2BD6-4A05-85FD-06DAACA78113 Q37519267-F1927564-B1F5-4873-958D-441EE80C0BBA Q37679265-92EE6D75-ABDF-41D8-A58E-03281C7EBD3D Q37730984-6EE35D03-C85F-4C90-AC03-A185F989DCCB Q38079317-4A6C30D1-1881-4DC0-831D-F9936103562B Q38161675-0F291ADD-2B28-4C99-B7B2-30F791F2D4D5 Q38176097-C637B659-907C-4D75-99E1-00F42C262DBF Q38219981-D29C4799-BFF8-4F19-B8C2-2CCC856085C7

P2860

Gantenerumab: a novel human anti-Aβ antibody demonstrates sustained cerebral amyloid-β binding and elicits cell-mediated removal of human amyloid-β

http://www.wikidata.org/entity/Q27674567

description

2012 nî lūn-bûn

@nan

2012 թուականին հրատարակուած գիտական յօդուած

@hyw

2012 թվականին հրատարակված գիտական հոդված

@hy

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

name

Gantenerumab: a novel human an ...... ted removal of human amyloid-β

@ast

Gantenerumab: a novel human an ...... ted removal of human amyloid-β

@en

Gantenerumab: a novel human an ...... ted removal of human amyloid-β

@nl

type

label

Gantenerumab: a novel human an ...... ted removal of human amyloid-β

@ast

Gantenerumab: a novel human an ...... ted removal of human amyloid-β

@en

Gantenerumab: a novel human an ...... ted removal of human amyloid-β

@nl

prefLabel

Gantenerumab: a novel human an ...... ted removal of human amyloid-β

@ast

Gantenerumab: a novel human an ...... ted removal of human amyloid-β

@en

Gantenerumab: a novel human an ...... ted removal of human amyloid-β

@nl

P1433

Q27674567-E16F9D43-B492-4B58-9080-2FD8F201CCCD

P1476

Q27674567-CEF4B6BD-2553-46B5-9942-7DF47BC2F911

P2093

Q27674567-0235D464-0DCB-468F-A5EF-8140674C79DE

Q27674567-04BD8CB7-B18E-4FE4-A9A7-E662E7C6B9DF

Q27674567-0513EEA9-14E8-4E8F-9EAD-A1C6D5199277

Q27674567-08A1F522-FDA0-499C-B56D-034B1FA8D776

Q27674567-10C04461-E390-4C00-AEF6-F77E2CD24269

Q27674567-146E6830-44BA-419B-9BB4-AAF9A2B01355

Q27674567-1DBC2BB8-974D-46B5-9974-107BA7FE4FA8

Q27674567-234FFBFE-050F-4C69-8599-C0FCDA582A29

Q27674567-28125F36-78AC-4808-885A-8F6488B1C87E

Q27674567-3F694F33-922A-4E68-A722-66E9FC5F1679

P304

Q27674567-3B6375D9-B1BA-47D4-B6EF-24430E189F15

P31

Q27674567-3B36E871-E4ED-47FC-938A-CFCCF4378E2C

P3181

Q27674567-9D507E28-5811-41CC-B932-B6E3B2008B19

P356

Q27674567-F53B119D-494F-4278-A85C-C1F8D01D0340

P433

Q27674567-C450710F-A9AC-43E1-B801-4CFB45801B61

P478

Q27674567-B4F9CBE2-D070-44B1-9B8C-0AAA3C39E60C

P50

Q27674567-8C22B6A8-970C-4A5F-9A75-BE158FEC6DBA

P577

Q27674567-1D11AEF7-9428-465D-8F46-C2E65961F042

P698

Q27674567-34A91688-FC36-4662-B874-6EAD03D2049D

P921

Q27674567-4606D263-FD5E-49C0-BF34-D0E3332EED4A

P3181

P356

JAD-2011-110977

P1433

Journal of Alzheimer's Disease

P1476

Gantenerumab: a novel human an ...... ted removal of human amyloid-β

@en

P2093

Bernd Bohrmann

http://www.w3.org/2001/XMLSchema#string

Christer Nordstedt

http://www.w3.org/2001/XMLSchema#string

Christine Rothe

http://www.w3.org/2001/XMLSchema#string

Francoise Gerber

http://www.w3.org/2001/XMLSchema#string

Frédéric Knoflach

http://www.w3.org/2001/XMLSchema#string

Hansruedi Loetscher

http://www.w3.org/2001/XMLSchema#string

Jörg Benz

http://www.w3.org/2001/XMLSchema#string

Jürg Messer

http://www.w3.org/2001/XMLSchema#string

Karlheinz Baumann

http://www.w3.org/2001/XMLSchema#string

Krisztina Oroszlan

http://www.w3.org/2001/XMLSchema#string

P304

49-69

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

1988597

http://www.w3.org/2001/XMLSchema#string

P356

10.3233/JAD-2011-110977

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

28

http://www.w3.org/2001/XMLSchema#string

P50

Wolfgang F. Richter

P577

2012-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

21955818

http://www.w3.org/2001/XMLSchema#string

P921